Abstract Introduction:KRAS Q61 mutations represent a heterogeneous molecular subgroup and account for 1–7% of allKRAS mutations in non-small cell lung cancer (NSCLC). The prognostic value of this cohort and its response to different treatment regimens remain unclear. Methods: Between 2011...

本期看点：1. 在研口服选择性KRAS...

D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC PR Newswire SHANGHAI, May 31, 2026 Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4 months...

Classified in: Health, Science and technology Subject: TRID3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4...

Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4 months in first-line KRAS G12C–mutant NSCLC (n=41) across all PD-L1 expression levels Combination of elisrasib with pembrolizumab achieves an ORR of 81.3% in first-line KRAS G12C–mutant NSCLC (n=48)...

Harlan, Kentucky Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4 months in first-line KRAS G12C–mutant NSCLC (n=41) across all PD-L1 expression levels Combination of elisrasib with pembrolizumab achieves an ORR of 81.3% in first-line KRAS G12C–mutant...